Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Daniel R. Principe, Alex Park, Matthew J. Dorman, et al.
Molecular Cancer Therapeutics (2018) Vol. 18, Iss. 3, pp. 613-620
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Won Jin Ho, Elizabeth M. Jaffee, Lei Zheng
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 9, pp. 527-540
Open Access | Times Cited: 878
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
Claudia X. Dominguez, Sören Müller, Shilpa Keerthivasan, et al.
Cancer Discovery (2019) Vol. 10, Iss. 2, pp. 232-253
Open Access | Times Cited: 618
Overcoming TGFβ-mediated immune evasion in cancer
Daniele V. F. Tauriello, Elena Sancho, Eduard Batlle
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 25-44
Open Access | Times Cited: 223
TGF-beta: a master immune regulator
Christopher Larson, Bryan Oronsky, Corey A. Carter, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 5, pp. 427-438
Closed Access | Times Cited: 160
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
Daniel R. Principe, Patrick W. Underwood, Murray Korc, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 155
KRAS drives immune evasion in a genetic model of pancreatic cancer
Irene Ischenko, Stephen D’Amico, Manisha Rao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 151
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
Angelo L. Grauel, Beverly Nguyen, David A. Ruddy, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 149
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu
Cancer Medicine (2020) Vol. 9, Iss. 21, pp. 8086-8121
Open Access | Times Cited: 143
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e002068-e002068
Open Access | Times Cited: 131
TGF-β Signaling and Resistance to Cancer Therapy
Maoduo Zhang, Ying Yi Zhang, Yongze Chen, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 122
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Tianyi Zhang, Yanxian Ren, Pengfei Yang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 10
Open Access | Times Cited: 94
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Conner Hartupee, Bolni Marius Nagalo, Chiswili Chabu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
Cancer-associated fibroblasts: how do they contribute to metastasis?
Mei Qi Kwa, Kate M. Herum, Cord Brakebusch
Clinical & Experimental Metastasis (2019)
Closed Access | Times Cited: 134
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
Daniel R. Principe, Matthew Narbutis, Sandeep Kumar, et al.
Cancer Research (2020) Vol. 80, Iss. 15, pp. 3101-3115
Open Access | Times Cited: 97
Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Heng Sheng Sow, Jiang Ren, Marcel Camps, et al.
Cells (2019) Vol. 8, Iss. 4, pp. 320-320
Open Access | Times Cited: 92
Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins
Sophie Liot, Jonathan Balas, Alexandre Aubert, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 68
Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
Daniel R. Principe, Lauren Chiec, Nisha Mohindra, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 68
Trials and tribulations of pancreatic cancer immunotherapy
Daniel R. Principe, Murray Korc, Suneel D. Kamath, et al.
Cancer Letters (2021) Vol. 504, pp. 1-14
Open Access | Times Cited: 62
Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy
Lei Li, Jia-Ru Wei, Jun Dong, et al.
Science Advances (2021) Vol. 7, Iss. 6
Open Access | Times Cited: 58
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
Yu-Heng Zhu, Jia-Hao Zheng, Qin-Yuan Jia, et al.
Cellular Oncology (2022) Vol. 46, Iss. 1, pp. 17-48
Closed Access | Times Cited: 58
T cells in pancreatic cancer stroma
Michelle R. Goulart, Konstantinos Stasinos, Rachel Elizabeth Ann Fincham, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 46, pp. 7956-7968
Open Access | Times Cited: 57
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
Anastasia E. Metropulos, Hidayatullah G. Munshi, Daniel R. Principe
EBioMedicine (2022) Vol. 86, pp. 104380-104380
Open Access | Times Cited: 48
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108111-108111
Open Access | Times Cited: 45
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113906-113906
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top